Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

Functional Role of WT1 in Prostate Cancer.

Fraizer GC, Eisermann K, Pandey S, Brett-Morris A, Bazarov A, Nock S, Ghimirey N, Kuerbitz SJ.

In: van den Heuvel-Eibrink MM, editor. Wilms Tumor [Internet]. Brisbane (AU): Codon Publications; 2016 Mar. Chapter 14.

2.

Connexin 43 expression is associated with increased malignancy in prostate cancer cell lines and functions to promote migration.

Zhang A, Hitomi M, Bar-Shain N, Dalimov Z, Ellis L, Velpula KK, Fraizer GC, Gourdie RG, Lathia JD.

Oncotarget. 2015 May 10;6(13):11640-51.

3.

Androgen up-regulates vascular endothelial growth factor expression in prostate cancer cells via an Sp1 binding site.

Eisermann K, Broderick CJ, Bazarov A, Moazam MM, Fraizer GC.

Mol Cancer. 2013 Feb 1;12:7. doi: 10.1186/1476-4598-12-7.

4.

Analysis of gene expression in prostate cancer epithelial and interstitial stromal cells using laser capture microdissection.

Gregg JL, Brown KE, Mintz EM, Piontkivska H, Fraizer GC.

BMC Cancer. 2010 Apr 28;10:165. doi: 10.1186/1471-2407-10-165.

5.

Measurement of wheat germ agglutinin binding with a fluorescence microscope.

Model MA, Reese JL, Fraizer GC.

Cytometry A. 2009 Oct;75(10):874-81. doi: 10.1002/cyto.a.20787.

6.

S-phase checkpoints regulate Apo2 ligand/TRAIL and CPT-11-induced apoptosis of prostate cancer cells.

Ray S, Shyam S, Fraizer GC, Almasan A.

Mol Cancer Ther. 2007 Apr;6(4):1368-78.

7.

Aurora-A/STK15/BTAK enhances chromosomal instability in bladder cancer cells.

Fraizer GC, Diaz MF, Lee IL, Grossman HB, Sen S.

Int J Oncol. 2004 Dec;25(6):1631-9.

PMID:
15547700
8.

Connexin 26 enhances the bystander effect in HSVtk/GCV gene therapy for human bladder cancer by adenovirus/PLL/DNA gene delivery.

Tanaka M, Fraizer GC, De La Cerda J, Cristiano RJ, Liebert M, Grossman HB.

Gene Ther. 2001 Jan;8(2):139-48.

9.

Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.

Zaia A, Fraizer GC, Piantanelli L, Saunders GF.

Anticancer Res. 2001 Jan-Feb;21(1A):1-10.

PMID:
11299720
10.
11.

PAX 8 regulates human WT1 transcription through a novel DNA binding site.

Fraizer GC, Shimamura R, Zhang X, Saunders GF.

J Biol Chem. 1997 Dec 5;272(49):30678-87.

12.

Transactivation of an intronic hematopoietic-specific enhancer of the human Wilms' tumor 1 gene by GATA-1 and c-Myb.

Zhang X, Xing G, Fraizer GC, Saunders GF.

J Biol Chem. 1997 Nov 14;272(46):29272-80.

13.

Expression pattern of WT1 and GATA-1 in AML with chromosome 16q22 abnormalities.

Patmasiriwat P, Fraizer GC, Claxton D, Kantarjian H, Saunders GF.

Leukemia. 1996 Jul;10(7):1127-33.

PMID:
8683991
14.

Differential function of Wilms' tumor gene WT1 splice isoforms in transcriptional regulation.

Hewitt SM, Fraizer GC, Wu YJ, Rauscher FJ 3rd, Saunders GF.

J Biol Chem. 1996 Apr 12;271(15):8588-92.

15.

Expression of the tumor suppressor gene WT1 in both human and mouse bone marrow.

Fraizer GC, Patmasiriwat P, Zhang X, Saunders GF.

Blood. 1995 Dec 15;86(12):4704-6. No abstract available.

16.

Transcriptional silencer of the Wilms' tumor gene WT1 contains an Alu repeat.

Hewitt SM, Fraizer GC, Saunders GF.

J Biol Chem. 1995 Jul 28;270(30):17908-12.

17.

GATA-1 transactivates the WT1 hematopoietic specific enhancer.

Wu Y, Fraizer GC, Saunders GF.

J Biol Chem. 1995 Mar 17;270(11):5944-9.

18.

Transcriptional regulation of the human Wilms' tumor gene (WT1). Cell type-specific enhancer and promiscuous promoter.

Fraizer GC, Wu YJ, Hewitt SM, Maity T, Ton CC, Huff V, Saunders GF.

J Biol Chem. 1994 Mar 25;269(12):8892-900.

19.

Deletion/frameshift mutation in the alpha 1-antitrypsin null allele, PI*QObolton.

Fraizer GC, Siewertsen M, Harrold TR, Cox DW.

Hum Genet. 1989 Nov;83(4):377-82.

PMID:
2807278
20.

In-frame single codon deletion in the Mmalton deficiency allele of alpha 1-antitrypsin.

Fraizer GC, Harrold TR, Hofker MH, Cox DW.

Am J Hum Genet. 1989 Jun;44(6):894-902.

Supplemental Content

Loading ...
Support Center